WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO
Sunnyvale, California – November 7, 2024 – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces that it has partnered a high value ingredient from its internal portfolio with a global ingredient manufacturer to fully develop, scale, and commercialize.
Through this partnership, Willow expects to receive payments for research and development (“R&D”) followed by a tiered profit share for 15 years after launch, if successful. The research program is expected to take 12 months to complete, with near-term payments for R&D to Willow of up to $1.3 million, should certain performance targets be met through development. The partner will be responsible for regulatory, manufacturing, and sales and marketing costs. The ingredient resulting from this collaboration will allow the partner to pursue commercialization in a $1 billion global segment that is currently dominated by a chemically synthesized product. Utilizing its fully integrated technology platform and strains previously developed, Willow and its partner are working to develop a high purity, sustainably produced natural ingredient that is bio-identical to that found in nature yet expected to be lower cost than chemically synthesized product.
“We are pleased to partner this ingredient that started as an internal program, with a global partner with commercial-scale manufacturing expertise and market access”, said Dr. Chris Savile, Willow’s President and Chief Executive Officer. “This partnership further validates our ability to select and develop products within large existing markets that can be improved with biomanufacturing, execute on the required science, and secure the appropriate commercialization partner.”
About Willow Biosciences Inc.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow’s FutureGrown™ and BioOxi™ platforms enable large-scale production with sustainability at its core. Willow’s R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers. For more information, visit www.willowbio.com.
FutureGrown™ and BioOxi™ are registered trademarks of Willow Biosciences Inc.
The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
Certain information contained herein has been obtained from published sources prepared by independent industry analysts and third-party sources (including industry publications, surveys and forecasts). While such information is believed to be reliable for the purposes used herein, Willow does not assume any responsibility for the accuracy of such information. The sources cited in this news release have not consented to the inclusion of any data from their reports, nor has Willow sought their consent.
VANCOUVER and CALGARY, April 12, 2019 /CNW/ – Makena Resources Inc. (“Makena“) (CSE: MKNA),...
Mountain View, CA
Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.